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Abstract
Background: Deep neck infections (DNIs) in HIV-infected patients often produce severe complications, even death.
Data on the incidence rates and risks of DNI among HIV-infected patients are scarce, particularly with the
widespread use of highly active antiretroviral therapy (HAART). We evaluated the incidence rates and risks for DNI
among HIV-infected patients and observed the long-term trends.
Methods: A total of 9888 new HIV-infected patients diagnosed in 2001–2007 were included and matched with
49440 randomly selected subjects. The HIV-infected subjects were offered free access to HAART. All subjects were
traced until December 2009. A Kaplan-Meier analysis generated the cumulative DNI incidence rate. The adjusted
hazard ratio was computed using Cox proportional hazard regressions.
Results: From the HIV-infected and comparison cohorts, 222 individuals (57.01 cases per 10000 person-years) and
735 individuals (35.54 cases per 10000 person-years) developed DNI, respectively. The log rank test indicated that
patients with HIV had a significantly higher 8-year incidence rate of DNI than the control group (P < 0.0001). The
adjusted hazard ratio for developing DNI after an HIV attack during the mean 3.94 years follow-up period was 1.59.
The incidence rate and relative risk of DNI were 74.58 (per 10000 person-years) and 2.05 (P < 0.0001). Both figures
were highest in the first follow-up year and decreased year-by-year thereafter.
Conclusion: The risk of developing DNI is significantly elevated among HIV-infected patients, even with free access
to HAART. Additional research is needed to examine the role of HAART in reducing the risk.
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Background
Deep neck infection (DNI) is a serious disorder defined
as infections that track along the facial planes of the
head and neck, which may result in abscess formation
or cellulitis as a result of bacterial invasion. This infec-
tion usually invades from other primary sites, usually
within the pharynx or oral cavity. The submandibular
(and sublingual), parapharyngeal, and retropharyngeal
spaces are the most clinically relevant spaces in the
neck. These spaces also connect to other important
structures such as the mediastinum, carotid sheath,
skull base and meninges in the head, and neck and
thorax, providing pathogens with easy access. Once in-
fection reaches these important areas, mortality rates
can be as high as 20–50% [1].
Deep neck infection is one of the most lethal infections
and can occur at any age and result in life-threatening com-
plications. In previous studies, the predisposing risk factors
for DNI included diabetes mellitus, drug abuse, congenital
neck cysts, age, and oral hygiene. Francisco Vieira et al.
suggested that immune suppression diseases, such as
chronic renal disease and hepatic disease, and chronic ster-
oid therapy for autoimmune disease could be risk factors
for DNI [2-8]. In Srivanitchapoom’s study, they emphasized
that clinical physicians were required to make certain
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assessments because of the potential for complications
when DNI was diagnosed in patients with compromised
immune systems [9]. The human immunodeficiency virus
(HIV) epidemic is one of the most important public health
problems of this century and has caused the deaths of a sig-
nificant number of immune-compromised patients. The
immune deficits of HIV-infected patients are broader and
include both abnormalities in humoral immunity and , in
the late stages of disease, neutrophil function .As a result,
bacterial infections frequently complicate HIV disease [10]
In an analysis of published reports on bacterial pneumonia,
rates were up to 25-fold higher among HIV-infected adults
than in the general population [11]. Consequently, it is rea-
sonable to project that more and more HIV-infected pa-
tients will suffer from DNI as their immune systems
gradually decline. One previous study indicated that
immune-compromised patients are more apt to develop
complicated and life-threatening DNI as compared to nor-
mal people [9]. However, the sample size was small and the
risk of DNI among HIV-infected patients was still un-
known, especially in the era of highly active antiretroviral
therapy (HAART).
Although highly active antiretroviral therapy (HAART),
the cornerstone of treating HIV infection, has been proven
effective at decreasing mortality, morbidity, opportunistic
infections, and hospitalization for HIV-infected patients
[12-14], it is not known whether HAART will also work to
decrease the risk of DNI. The Taiwanese government has
provided all HIV-infected citizens with free access to
HAART from April 1997 to the present day, making it pos-
sible to study the effect of widespread use of HAART on
the risk of developing DNI among HIV-infected patients.
To our knowledge, despite some case reports, large
sample data regarding the exact frequency and risk
of DNI among HIV-infected patients are still lacking.
Our study’s goal was to investigate the risk of DNI




This study used a data set released by the Taiwan National
Health Research Institute in 2011. Taiwan’s National
Health Insurance program was instituted in March 1995
and provides coverage for over 98% of the residents. The
National Health Research Institutes transferred national
health insurance reimbursement data into files for re-
search. These files provided the detailed health care ser-
vices information for each patient, including all payments
for outpatient visits, hospitalizations, and prescriptions.
For each outpatient visit or hospitalization, the data
contained up to 3–5 diagnoses coded under the Inter-
national Classification of Diseases, Ninth Revision, along
with the prescription drugs and doses, special treatments
(such as surgery), and dates of these orders. This study
was conducted according to the Declaration of Helsinki
and was approved by Institutional Review Boards (IRBs)
at Chi Mei Medical Center (10109-E01).The IRBs waived
the need for informed consents (written and oral) from
the participants because the data set used in this study
consists of nationwide, unidentifiable, secondary data
released to the public for research purposes. This waiver
does not adversely affect the rights and welfare of
the subjects.
Study sample
The study cohort was comprised of all the patients, from
January 1, 2002 to December 31, 2007, who were newly
diagnosed for treatment of HIV infection in more than 3
outpatient visits or in 1 hospitalization claim in Taiwan
(International Classification of Diseases, 9th Revision,
Clinical Modification Code 042–044, V08 ). Since DNI
was defined as a severe infection in the deep neck space,
patients assigned ICD-9-CM codes 528.3 (cellulitis and
abscess of oral soft tissues; Ludwig angina), 478.22
(parapharyngeal abscess), 478.24 (retropharyngeal ab-
scess), and 682.11 (cellulitis and abscess of neck), as well
as patients with peritonsillar abscesses, sialoadenitis,
salivary gland abscesses, superficial abscesses, and facial
abscesses were excluded. Patients who had been diag-
nosed with DNI before their HIV infection or had a
history of congenital neck cysts (such as thyroglossal
duct and branchial cleft cysts) were also excluded. Fi-
nally, a total of 9888 HIV-infected patients were in-
cluded in this study.
Control group
For each HIV case, five controls without HIV were ran-
domly selected in 2000 from the longitudinal Health In-
surance Database 2000, a data subset of the National
Health Insurance Research database (NHIRD) that con-
tains all the claim data (from 1996 to 2009) for one mil-
lion beneficiaries (4.34% of the total population). The
controls were matched by gender, age, and index date.
The index date for the HIV patients was the date of their
first registry and the index date for the controls was cre-
ated by matching the date of the HIV subject’s index
date. As with the HIV patients, the patients diagnosed
with DNI before the index date were excluded.
Each patient was followed up to determine the incidence
of DNI until the end of 2009 or was censored because
of death. Incidence rates (per 10000 person years), inci-
dence rate ratios (IRRs), and hazard ratios (HRs) for DNI
were analysed. Comorbidities were also defined based on
the claims data, including drug abuse (ICD-9-CM codes
304–305 and 965.00–965.09), diabetes mellitus (ICD-9-
CM codes 250.00–250.90), liver cirrhosis (ICD-9-CM
codes 571.2, 571.5–571.6), chronic kidney disease (ICD-9-
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CM codes 585–586), and autoimmune disease (ICD-9-
CM codes 279.4, 710, 711.1–711.2, and 714). We in-
cluded these comorbid conditions if the condition
occurred either in the inpatient setting or in two or
more ambulatory care claims coded 12 months before
the index medical care date.
Statistical analysis
Descriptive statistical analyses using Pearson χ2 tests
were done to compare the HIV group and the control
group in terms of sociodemographic characteristics and
comorbidities. The incidence rate was calculated as the
number of DNI cases identified during the follow-up, di-
vided by the total person-years for each group by sex,
age, and follow-up months. The risk of getting DNI was
compared between the HIV group and the non-HIV
group by estimating the incidence rate ratio using
Poisson regression. Adjusted HRs for getting DNI were
also estimated by Cox proportional hazard models.
Kaplan-Meier analysis was used to calculate the cumula-
tive incidence rates of DNI in the two cohorts, and the
log rank test was used to analyse the differences between
the survival curves. Kaplan-Meier analysis was also used
to estimate the survival rate for HIV-infected patients in
the DNI and no-DNI groups. Moreover, Pearson χ2 tests
were done to compare the pattern of losses follow up
between study cohorts and control cohorts in the each
year to show whether the follow up was similar or not.
All analyses were performed using SAS software, version
9.3 (SAS Institute, Cary, NC), and the statistical signifi-
cance level was set at two-sided p < 0.05.
Results
Table 1 describes the distribution of demographic char-
acteristics and select comorbidities for both the study
and comparison cohorts. After matching for sex and
age, the results demonstrate that patients with HIV were
more likely to have the comorbidities diabetes mellitus
(P = 0.0106), drug abuse (P < 0.0001), chronic renal fail-
ure (P = 0.0005), liver cirrhosis (P < 0.0001), and auto-
immune disease (P < 0.0001) than the control groups.
In Table 2, out of the total study sample of 9888
HIV-infected patients, 222 individuals (57.01/per 10000
person-years) developed DNI during the mean 3.94-
year follow-up period. Out of the control sample of
49440 subjects without HIV, 735 individuals (35.54/per
10000 person-years) developed DNI. With the exception
of the follow-up beyond 3 years (IRR = 1.26, P = 0.1255,
n = 53 cases) after the HIV infection was diagnosed, the
risk of developing DNI was significantly elevated in the
HIV-infected groups in all ages, genders, and follow-up
time frames.
The incidence rate and relative risk of DNI in the
HIV-infected patients were 74.58 (per 10000 person-
years) and 2.05 (P < 0.0001), and both were highest in
the first follow-up year and then decreased on a yearly
basis for the remainder of the follow-up. Beyond the 3-
year follow-up, the incidence rate and the IRR were even
lower at 45.08 (per 10000 person-years) and 1.26, which
was not significantly elevated (P = 0.1255) as compared
to the control group.
The details of the crude and adjusted HRs for DNI,
based on the Cox proportional hazard regression analysis,
are also carried out by cohort. After adjusting for the pa-
tient’s age, gender, drug abuse, chronic renal failure, liver
cirrhosis, autoimmune disease, and diabetes mellitus, the
HR for developing DNI during the mean 3.93-year follow-
up period was 1.59 (95% CI, 1.358–1.862; P < 0.00001) for
patients with HIV as compared to patients in the compari-
son cohort.
The Kaplan-Meier analysis indicated that patients with
HIV had a significantly higher incidence rate of DNI
than the patients in the comparison cohort (P < 0.0001).
The results of this analysis are presented in Figure 1.
The Kaplan-Meier analysis was also used to estimate the
survival rate for HIV-infected patients in the DNI and
non-DNI groups. There was no significant decrease in
the survival rate of the patients with HIV who had suf-
fered from DNI attacks (P = 0.9684) as can be seen in
Figure 2. There was a significant difference on the losses
of follow-up in the first 2 years between the study co-
horts and control cohorts in Table 3.
Table 1 Demographic characteristics and comorbid
medical disorders for HIV patients and comparison group
patient in Taiwan
HIV (N = 9888) Controls (N = 49440) P-value
Age - 0 ~ 30 3870 (39.14) 19329 (39.10) 0.9935
- 30-39 3695 (37.37) 18505 (37.43)
- ≧40 2323 (23.49) 11606 (23.47)
Gender -Female 1089 (11.01) 5445 (11.01) 1.0000
-Male 8977 (88.99) 43995 (88.99)
Baseline comorbidity
DM -Yes 194 (1.96) 792 (1.60) 0.0106
-No 9694 (98.04) 48648 (98.40)
Drug abuse -Yes 316 (3.20) 129 (0.26) <0.0001
-No 9572 (96.80) 49311 (99.74)
Renal -Yes 34 (0.34) 85 (0.17) 0.0005
-No 9854 (99.66) 49355 (99.83)
Liver Cirrhosis -Yes 83 (0.84) 124 (0.25) <0.0001
-No 9805 (99.16) 49316 (99.75)
Autoimmune -Yes 54 (0.55) 82 (0.17) <0.0001
-No 9834 (99.45) 49358 (99.83)
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Discussion
Our results indicated that there may be more than just
sporadic cases of DNI among HIV-infected patients,
since the risk of DNI after an HIV attack was signifi-
cantly elevated even with free access to HAART. In our
study, the overall incidence of DNI in HIV-infected pa-
tients in Taiwan was 57.01 (per 10000 person-years), the
first time this has been estimated in the world. The inci-
dence risk ratio as compared to the control group was
1.60. After adjusting for the confounders, the HR was
1.59 (P < 0.0001). After adjusting for the other risks, we
found that the risk of having a deep neck infection
increased by 59% post-HIV infection. The log rank test
indicated that patients with HIV had a significantly
higher incidence rate of DNI than the patients in the
comparison cohort (P < 0.0001).
In this study, the mean observation duration was
3.94 years (range: 2–8 years). This duration of time was
sufficient to observe the trend and change in the risk of
DNI among the HIV-infected patients under HAART. If
we compare the incidence rate by follow-up years in the
study group with the control group, the incidence rate
among patients without HIV infection was relatively
stable at about 35.55 ± 1.53 (per 10000 person-years).
After having HIV, the incidence rate for DNI was
74.58 (per 10000 person-years) and the incidence risk
Table 2 Risk of infection and soft tissue abscess for HIV patients and controls
Characteristics HIV Controls IRR (95 % CI) P
N infection PY# Rate* N infection PY# Rate*
All 9888 222 38937.96 57.01 49440 735 206793.00 35.54 1.60 (1.38-1.86) <0.0001
Age
0 ~ 30 3870 92 16050.86 57.32 19329 277 82632.95 33.52 1.71 (1.35-2.16) <0.0001
30 ~ 40 3695 71 14457.23 49.11 18505 251 76485.96 32.82 1.50 (1.15-1.95) 0.0027
γ 40 2323 59 8429.87 69.99 11606 207 47674.09 43.42 1.61 (1.21-2.15) 0.0012
Gender
Male 8799 194 34755.23 55.82 43995 650 184421.29 35.25 1.58 (1.35-1.86) <0.0001
Female 1089 28 4182.73 66.94 5445 85 22371.71 37.99 1.76 (1.15-2.71) 0.0093
Follow-up years
<1 9888 71 9519.69 74.58 49440 179 49317.37 36.30 2.05 (1.56-2.70) <0.0001
1-2 9422 54 9351.26 57.75 49198 167 49088.12 34.02 1.70 (1.25-2.31) 0.0007
2-3 9296 44 8309.14 52.95 48972 159 43951.53 36.18 1.46 (1.05-2.04) 0.0253
≧3 7231 53 11757.88 45.08 38481 230 64435.98 35.69 1.26 (0.94-1.70) 0.1255
#PY, person-years.
*Rate: per 10000 person-years.
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Figure 1 Incidence rate of DNI for HIV patients and controls.
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ratio was 2.05 (P < 0.0001) in the first follow-up year.
Both the incidence rate and incidence risk ratio were
highest in the follow-up years. In theory, the incidence
of DNI should increase gradually, following the viral rep-
lication and CD4+ cell decline of the HIV-infected pa-
tients. It is interesting that the incidence rate and
relative risk of DNI gradually decreased in the HIV-
infected patients throughout the follow-up period. As
time passed, the incidence risk ratio became lower and
lower. Beyond the 3-year follow-up, the incidence of
DNI and risk ratio were still higher than the control
group, but they were lower than the previous 3 years,
even down to 45.08 (per 10000 person-years) and 1.26
(P = 0.1255), which was not significantly elevated as
compared to the control group.
HAART could play a role in this unanticipated result.
Although we can hypothesize that this result is largely due
to the well-known immune restoration consequences of
HAART [15], we also need to consider the other cofactors
implicated in this reduced incidence of DNI. HIV-infected
patients are apt to develop aggressive periodontal disease
and the associated ulcerative gingivitis, which can result in
marked gingival recession and other oral lesions [16]. The
increased risk of DNI could be the result of HIV damaging
the immune system and decreasing resistance to oral in-
fections, which was then further compounded by poor
oral hygiene.
Even immune suppression for HIV-related cancer
and related treatments may be a predisposing factor for
DNI among HIV-infected patients. HAART has had a
major impact on the reduction of plasma HIV RNA
and the increase in peripheral CD4+ cells. It can also
reduce the incidence of several opportunistic infections,
including odontogenic infections and malignancies, es-
pecially AIDS-defining cancers [17,18]. HAART may
have the capacity of effectively reducing the incidence
rate of DNI.
Because of the side effects and the need for taking
HAART continuously at the outset, not all HIV-infected
patients accept HAART immediately after their HIV
diagnosis. The timing of the initiation of HAART and
the regimens are based on the guidelines recommended
in the United States [19]. Following the gradual decrease
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Figure 2 Survival rate for HIV-infected patients in the DNI and non-DNI groups.
Table 3 Losses of follow-up for HIV patients and controls
Interval HIV (N = 9888) Controls (N = 49440) P-value**
N* Number of losses follow up N* Number of losses follow up
0-1 9888 395 (3.99) 49440 63 (0.13) <0.0001
1-2 9422 72 (0.76) 49198 59 (0.12) <0.0001
2-3 9296 2021 (21.74) 48972 10332 (21.10) 0.1645
3-4 7231 3522 (48.71) 38481 18064 (46.94) 0.0058
*N: Number of beginning.
** p-value obtained by chi-square.
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generally conform to the criteria and accept HAART.
With more and more HIV-infected patients accepting
HAART, the incidence of DNI and its relative risk
should gradually decline to a steady level. This trend and
the unexpected result suggested that HAART may de-
crease the risk of DNI among HIV-Infected patients.
Another possible consideration for the decrease in the
incidence of DNI in the follow-up years may be the fact
that the HIV patients whose immune systems were the
most compromised did not survive, thereby decreasing
the number of patients with the more severe immunity
issues. We tried to evaluate the difference in the survival
rates between the HIV patients with a history of DNI
and the HIV patients without a history of DNI in order
to rule out this hypothesis. In our study, there was no
significant decrease in the survival rate of the patients
with HIV who had suffered from DNI. On the other
hand, there was a significant difference on the losses of
follow-up between the study cohorts and control co-
horts, so the time-decline in DNI rates on the HIV co-
hort may be explained by differences on the losses of
follow-up in this study. Because of such a limitation,
additional research is needed to examine the role of
HAART in reducing the risk of DNI among HIV-
infected patients.
The use of administrative data to assess the contribu-
tion of HIV infection to DNI is subject to several biases
such as information bias and selection bias. For example,
it is well known that patients with drug abuse have in-
creased rates of periodontitis. It may cause the selection
bias which might affect the result of the study. In order
to avoid such a bias, we took the diseases which could
be predisposing factors of DNI in previous studies in-
cluding drug abuse as comorbidities for both the study
and comparison cohorts. After adjusting for the patient’s
comorbidities, the effect of the bias which had affected
the HR could be minimized. Likewise co-infection by HPV
in patients having sex with men may increase the rate of
cancer of oral cavity. If it is the case, the risk of oral cancer
might increase significantly in the patients with HIV in
comparison to the controls. However, the incidence rate ra-
tio between HIV-infected patients and the controls for oral
cancer was 1.23 (95%CI = 0.63-2.41) in the present study.
Hence, the effect of confounding variable of HPV infection
in present study remains to be proved.
There were several limitations in the present study. First,
the diagnosis of DNI was based on the diagnostic code
registered by the physicians responsible for the treatment
of the patients and was not corroborated by the investiga-
tors. Second, the risk of DNI after an HIV attack was se-
verely underestimated, because all of the HIV-infected
patients in this study were offered free access to HAART.
The real risk of DNI among HIV-infected patients would
need to be estimated with untreated patients, but political
and ethical reasons prevent such a study in Taiwan. None-
theless, we still successfully proved the elevated risk of
DNI among HIV-infected patients even when they had
free access to HAART. The influence of HAART on HIV-
infected patients should be compared using untreated pa-
tients, but, of course, political and ethical reasons again
prevent this study. Fortunately, the long-term trend could
be clearly observed in this study. Additional investigations
on this issue are needed. Third, although the Taiwanese
government will provide all HIV-infected citizens with free
access to HAART, the HIV-infected patients make their
own decisions as to when to start HAART. The degree of
compliance of the patients using HAART was also not
covered in this study.
Conclusions
In conclusion, we believe this is the first attempt at in-
vestigating epidemiological data on DNI among HIV-
infected patients in a nationwide population-based
study. The results of the present study indicate the risk
of DNI is significantly elevated among HIV-infected pa-
tients, even with free access to HAART. Additional re-
search is needed to examine the role of HAART in
reducing the risk.
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